Conceptus (NASDAQ: CPTS) was downgraded by equities research analysts at WBB Securities from a “speculative buy” rating to a “hold” rating in a research note issued to investors on Tuesday. They currently have a $19.50 price target on the stock, up from their previous price target of $16.00.
Other equities research analysts have also recently issued reports about the stock. Analysts at Wunderlich raised their price target on shares of Conceptus from $14.00 to $18.00 in a research note to investors on Tuesday. They now have a “hold” rating on the stock. Separately, analysts at GARP Research reiterated a “buy” rating on shares of Conceptus in a research note to investors on Monday. Finally, analysts at Piper Jaffray (NYSE: PJC) upgraded shares of Conceptus from a “neutral” rating to an “overweight” rating in a research note to investors on Monday.
Conceptus opened at 18.66 on Tuesday. Conceptus has a 1-year low of $9.68 and a 1-year high of $20.20. The company’s market cap is $584.2 million.
The company last announced its quarterly results on Thursday, April 26th. It reported ($0.09) earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.13) EPS by $0.04. The company’s quarterly revenue was up 9.0% on a year-over-year basis. Analysts expect that Conceptus will post $0.05 EPS next quarter.
Conceptus, Inc. develops, manufactures and markets the Essure permanent birth control system, a medical device for women.